Xenon Pharmaceuticals XENE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $0— | $0— | $0— | $7.5M— | ||
| $88.51M+44.6% | $87.7M+47.5% | $77.05M+35.3% | $74.99M+50.9% | $61.2M+38.3% | ||
| $23.82M+25.1% | $22.07M+22.6% | $19.28M+15.4% | $19.24M-0.8% | $19.04M+28.7% | ||
| $112.33M+40.0% | $109.77M+41.7% | $96.34M+30.8% | $94.23M+36.4% | $80.24M+35.9% | ||
| -$112.33M-54.4% | -$109.77M-41.7% | -$96.34M-30.8% | -$94.23M-36.4% | -$72.74M-23.2% | ||
| $7.46M-8.2% | $5.04M-36.5% | $6.12M-42.1% | $8.9M-18.0% | $8.12M-29.5% | ||
| -$104.87M-62.3% | -$104.72M-50.6% | -$90.22M-43.0% | -$85.33M-46.5% | -$64.62M-36.0% | ||
| -$2.57M-702% | $538K+114% | $677K+312% | -$626K-88.0% | $427K+3.6% | ||
| -$102.3M-57.3% | -$105.26M-60.3% | -$90.9M-44.8% | -$84.71M-46.2% | -$65.05M-35.7% | ||
| -$1.17-41.0% | -$1.31-56.0% | -$1.15-42.0% | -$1.07-42.7% | -$0.83-33.9% | ||
| -$111.74M-55.0% | -$109.16M-42.1% | -$95.7M-31.1% | -$93.6M-36.7% | -$72.08M-23.3% | ||
| -$112.33M-54.4% | -$109.77M-41.7% | -$96.34M-30.8% | -$94.23M-36.4% | -$72.74M-23.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Xenon Pharmaceuticals profitable?
- Xenon Pharmaceuticals is not currently profitable: it reported a net loss of $383.2M over the trailing twelve months, a -4612.1% net margin.
- What is Xenon Pharmaceuticals's earnings per share?
- Xenon Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.70.
- Where does Xenon Pharmaceuticals's income statement data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.